Creative Medical Technology (CELZ) vs Calidi Biotherapeutics (CLDI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Creative Medical Technology is the larger company by market cap ($6.5 million vs $3.8 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELZ | CLDI |
|---|---|---|
| Share price | $0.8604 | $1.04 |
| Market cap | $6.53M | $3.82M |
| 1-day change | -2.45% | +2.97% |
| EPS (TTM) | $-2.07 | $-36.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.25 | $27.84 |
| 52-week low | $0.62 | $0.986 |
| Distance from 52-week high | -86.23% | -96.26% |
| Analyst consensus | none | — |
| Avg. price target upside | +2224.50% | — |
| Average volume | 6.77M | 255.53K |
| Shares outstanding | 7.59M | 3.68M |
| Employees | 4 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Creative Medical Technology
CELZ stock →Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4 employees
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
CELZ vs CLDI FAQ
Which is bigger, Creative Medical Technology or Calidi Biotherapeutics?
Creative Medical Technology (CELZ) is larger, with a market capitalization of $6.53M compared with $3.82M for Calidi Biotherapeutics (CLDI).
Are Creative Medical Technology and Calidi Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.